Cannabinoid Biosynthesis Market Share

Report ID: 4142
Published Date: Nov 21, 2025
Report Format: PDF, PPT

Buy Now

Asia Pacific industry is anticipated to hold largest revenue share by 2035. The growth of the market can be attributed majorly to the increasing cases of depression and anxiety that are rapidly expanding the use of medical marijuana. Based on a report released by the National Library of Medicine (NL) in 2021, the prevalence of depression was stated to be 59.2% in the region. Furthermore, the legalization of cannabis and initiatives by the government to boost its production are also expected to boost the market growth in the region. In India, Uttarakhand was the first state to legalize the commercial cultivation of cannabis. Moreover, the Uttarakhand government in association with the India Industrial Hemp Association introduced the project for its cultivation.

Browse key industry insights with market data tables & charts from the report:

Cannabinoid Biosynthesis Market Size, Growth Forecasts 2026-2035

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of cannabinoid biosynthesis is estimated at USD 29.63 billion.

The global cannabinoid biosynthesis market size was more than USD 25.88 billion in 2025 and is anticipated to grow at a CAGR of over 16.1%, reaching USD 115.16 billion revenue by 2035.

Asia Pacific industry is predicted to hold the largest revenue share by 2035, impelled by rising cases of depression and anxiety expanding the use of medical marijuana.

Key players in the market include Amyris, Inc., Willow Bioscience Inc., Cronos Group, Zymergen Inc., Constellation Brands, Inc., Jazz Pharmaceuticals plc, Canopy Growth Corporation, InMed Pharmaceuticals Inc., Hyasynth Biologicals Inc., Renew Biopharma, Inc.